Kindred Biosciences (KIN) Reports CereKin KB010 Missed Primary Endpoint
Tweet Send to a Friend
Kindred Biosciences (NASDAQ: KIN) announced that its pivotal field study (KB010) of CereKin, an interleukin-1 inhibitor for the control of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
